1. |
Redman MW, Allegra CJ. The master protocol concept. Semin Oncol, 2015, 42(5): 724-730.
|
2. |
Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med, 2017, 377(1): 62-70.
|
3. |
Herbst R, Rubin E, LaVange L, et al. Issue brief: conference on clinical cancer research. Available at: http://www.focr.org/sites/default/files/.CCCR12 Master Protocol.pdf.
|
4. |
Conley BA, Doroshow JH. Molecular analysis for therapy choice: NCI MATCH. Semin Oncol, 2014, 41(3): 297-299.
|
5. |
Kummar S, Williams PM, Lih CJ, et al. Application of molecular profiling in clinical trials for advanced metastatic cancers. J Natl Cancer Inst, 2015, 107(4): djv003.
|
6. |
Barker AD, Sigman CC, Kelloff GJ, et al. I-SPY2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharm Ther, 2009, 86(1): 97-100.
|
7. |
Kaplan R, Maughan T, Crook A, et al. Evaluating many treatments and biomarkers in oncology: a new design. J Clin Oncol, 2013, 31(36): 4562-4568.
|
8. |
Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov, 2011, 1(1): 44-53.
|
9. |
Sleijfer S, Bogaerts J, Siu LL. Designing transformative clinical trials in the cancer genome era. J Clin Oncol, 2013, 31(15): 1834-1841.
|
10. |
Herbst R, Rubin E, LaVange L, et al. Design of a disease-specific master protocol. Presented at the friends of cancer research/brookings conference on clinical cancer research, Washington, DC, November14, 2012.
|
11. |
Herbst RS, Gandara DR, Hirsch FR, et al. Lung master protocol (Lung-MAP)-a biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400. Clin Cancer Res, 2015, 21(7): 1514-1524.
|
12. |
Steuer CE, Papadimitrakopoulou V, Herbst RS, et al. Innovative clinical trials: the LUNG-MAP study. Clin Pharmacol Ther, 2015, 97(5): 488-491.
|
13. |
Clinical trial designs for studying targeted therapies. Available at: https://am.asco.org/clinical-trial-designs-studying-targeted- therapies.
|
14. |
Berry DA. The brave new world of clinical cancer research: adaptive biomarker-driven trials integrating clinical practice with clinical research. Mol Oncol, 2015, 9(5): 951-959.
|
15. |
Redig AJ, Jänne PA. Basket trials and the evolution of clinical trial design in an era of genomic medicine. J Clin Oncol, 2015, 33(9): 975-977.
|
16. |
姜辉, 吕肖芳, 张丽, 等. 代谢组学在中医药现代化研究中的应用. 中华中医药杂志, 2013, 28(3): 588-590.
|
17. |
赵晨, 张晓雨, 胡嘉元, 等. 中医同证候系疾病临床研究母方案设计方法. 中医杂志, 2018, 59(2): 111-115.
|
18. |
中国心血管病报告编写组. 《中国心血管病报告 2016》概要. 中国循环杂志, 2017, 32(6): 521-530.
|
19. |
Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. Eur Heart J, 2007, 28(20): 2525-2538.
|
20. |
邓伏雪, 王小娟, 胡云凤, 等. 急性心肌梗死并发首次心力衰竭患者在院死亡率及临床预后分析. 西安交通大学学报(医学版), 2015, 36(1): 135-140.
|
21. |
杨利. 邓铁涛教授" 冠心三论”. 湖南中医药导报, 2004, 10(6): 8-10.
|
22. |
王东海, 董波. 冠心病心绞痛证型分布的回顾性分析. 世界中西医结合杂志, 2015, 10(3): 387-389.
|
23. |
张敏州, 王磊. 邓铁涛教授论治冠心病介入术后病证的学术思想探析. 中医药管理杂志, 2006, 14(1): 32-33.
|
24. |
霍根红, 李娟. 中医药防治 PCI 术后支架内血栓研究述评. 中医学报, 2016, 31(3): 426-429.
|
25. |
Fox JL. Master protocol for squamous cell lung cancer readies for launch. J Nat Biotechnol, 2014, 32(2): 116-118.
|